Healthcare Industry News: excimer laser
News Release - April 28, 2008
Spectranetics Reaches Settlement with Medtronic
COLORADO SPRINGS, Colo.--(HSMN NewsFeed)--Spectranetics Corporation (Nasdaq:SPNC ) today announced that it has settled its intellectual property dispute with Medtronic, and that Medtronic has taken a license to the patent at issue in the litigation. Terms of the settlement agreement were not disclosed.“We are pleased to reach this settlement with Medtronic. This license validates our strong intellectual property position in the area of thrombus management with aspiration catheters,” stated John G. Schulte, Spectranetics’ President and Chief Executive Officer.
About Spectranetics
Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company’s disposable catheters use high-energy “cool” ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit www.spectranetics.com.
Source: Spectranetics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
